Shares of Kura Oncology surged 11.3% to $13.80 after a regulatory filing revealed President and CEO Troy Wilson scooped up another 100,000 shares for roughly $1.24 million at $12.39 per share on August 24. Just one week earlier, on August 17, Wilson made an identical-sized purchase — 100,000 shares at $11.12 apiece — worth approximately $1.11 million. Together, the back-to-back buys represent about $2.35 million of the founder-CEO's personal capital deployed in eight days, a signal Wall Street rarely ignores.

  • Two Purchases in Eight Days Send a Louder Message Than One. A single insider buy can be routine; a rapid-fire second purchase suggests conviction. Wilson now holds 379,194 shares through one trust, another 300,000 through a charitable trust, and 435,456 shares directly — and those totals predate the August 24 buy. With insiders owning roughly 1.5% of Kura shares, worth about $17 million , Wilson is meaningfully increasing his personal exposure at a moment when the stock still trades well below a median analyst price target of $24 .

  • The Cancer Drug Behind the Bet Is Gaining Traction Fast. Wilson's buying spree follows a strong Q2 earnings report. Kura's FDA-approved leukemia pill generated $9.1 million in net product revenue in Q2, up 57% from Q1, supported by about 115 new patient starts and over 250 total prescriptions.

The company beat Wall Street estimates on both revenue ($20.87 million vs. $20.16 million expected) and adjusted loss ($0.77 vs. $0.88 expected). For a drug only two full quarters into its U.S. launch, those numbers suggest doctors are choosing it.

  • $519 Million in Cash Buys Time, but Losses Are Still Large. Cash fell from $667 million at year-end 2025 to $519 million by June 30, and the company's accumulated deficit widened to $1.32 billion.

Kura expects its cash plus $180 million in collaboration payments from partner Kyowa Kirin to fund operations through pivotal late-stage trial results anticipated in 2028. That runway matters: if the trial succeeds, it could unlock a market management has sized at $7 billion across all stages of acute myeloid leukemia .

  • The Stock Is Still Cheap — or Still Risky. Over the past 52 weeks, KURA has traded between $7.36 and $12.90 , meaning today's $13.80 prints a new high. Yet at roughly $1.2 billion in market value, the stock prices in only a fraction of peak drug potential. The CEO is betting his own money that investors will eventually close that gap.